Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $150 t...
https://register.epo.org/application?number=EP21818146
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Journal for ImmunoTherapy of C...
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(3.68) per share which beat the analyst consensus estimate of $(8.00) b...
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the strong clinical successes in o...
Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (d...
